GHK-Cu (copper tripeptide-1) is a naturally occurring tripeptide of glycine, histidine, and lysine bound to a copper ion. In compounding, it appears in two distinct contexts: as a topical formulation applied to skin and hair, and as an injectable preparation. The two forms sit on opposite sides of an important regulatory line.
GHK-Cu ranks as the #12 most-prescribed compounded product on ScriptLinkRx, based on cumulative order volume across clinics ordering through ScriptLinkRx as of mid-2026 — a figure that consolidates both its topical cream and injectable forms into a single entry. Its position on that list reflects steady interest from aesthetic and wellness practices, but its regulatory footing differs sharply depending on the dosage form and, critically, the claims a clinic attaches to it.
What GHK-Cu Is
GHK-Cu is a copper-binding peptide identified in human plasma, saliva, and urine. The glycyl-L-histidyl-L-lysine (GHK) sequence has high affinity for copper(II) ions, and the resulting complex is the form most often referenced in cosmetic and compounding contexts.
Copper peptides in general are studied as signaling molecules involved in tissue remodeling, and copper is an essential trace element with defined biological roles. This article does not assert any clinical outcome for GHK-Cu; the compound is not FDA-approved as a drug for any indication, and its mechanistic profile in humans remains an area of ongoing research rather than established therapeutics. Providers evaluating it should treat efficacy questions as unsettled.
How Providers Use It in Practice
GHK-Cu is ordered primarily by med spas and aesthetic dermatology practices, and to a lesser extent by longevity and integrative wellness clinics. In practice, topical GHK-Cu formulations are the more common form clinics stock or dispense, typically in the context of skin- and hair-focused programs.
Some providers incorporate injectable GHK-Cu into practice offerings as well, though this form carries materially different regulatory and quality considerations (discussed below). Because the compound has no approved indication, any clinical use is at the prescriber's professional discretion and responsibility, and clinics should document their rationale accordingly rather than relying on marketing narratives.
Forms and Combinations Available Through Compounding
Compounding pharmacies prepare GHK-Cu in several formats:
- Topical creams, serums, and gels — the most widely encountered form, often supplied at pharmacy-determined concentrations for application to skin or scalp.
- Injectable solutions — sterile preparations that require compliance with sterile-compounding standards.
- Oral capsules — a less common presentation prepared by some pharmacies on prescriber request.
- Combination topicals — GHK-Cu is sometimes formulated alongside other cosmetic or dermatologic actives in a single vehicle, subject to the compounding pharmacy's formulation controls.
Compounding exists for GHK-Cu largely because there is no FDA-approved GHK-Cu drug product; a compounded preparation allows a licensed pharmacy to prepare a patient-specific formulation on receipt of a valid prescription. This document does not provide concentrations, application frequency, or dosing of any kind — those determinations belong to the prescriber and the dispensing pharmacy.
Regulatory Status and Provider Considerations
GHK-Cu's regulatory picture depends heavily on form and, above all, on the claims made about the product.
The cosmetic-versus-drug line
Under U.S. law, whether a product is a cosmetic or a drug is determined largely by its intended use, and intended use is inferred substantially from the claims made about it. Copper tripeptide-1 has long appeared as an ingredient in over-the-counter cosmetic serums and creams, where it is marketed for general appearance-related use and regulated as a cosmetic — a category that does not undergo FDA pre-market approval. The moment a product is promoted to treat, cure, mitigate, or affect the structure or function of the body — for example, claims to reverse aging, regrow hair as a therapy, or heal a condition — it may be treated as a drug (or a drug-cosmetic), triggering drug requirements. As of July 2026, this claims-driven distinction is the single most important compliance factor for clinics offering topical GHK-Cu: identical formulations can be classified differently based on how they are described in marketing and patient-facing materials.
Clinics should avoid disease- or rejuvenation-treatment claims in their advertising and instead work within the professional prescriber-patient relationship for any use intended to affect the body's structure or function through a compounded prescription.
Injectable GHK-Cu and the Category 2 change
Injectable GHK-Cu had been placed in Category 2 of FDA's interim list of bulk drug substances nominated for use in compounding under section 503A — the category for substances associated with significant safety risks that FDA had flagged as not appropriate for compounding pending further review.
On April 15, 2026, FDA announced it was removing a group of peptides — including injectable GHK-Cu — from Category 2. It is essential to read this change narrowly: removal from Category 2 does not mean GHK-Cu is FDA-approved, cleared, or affirmatively endorsed for compounding. It means the substance was moved out of the "significant safety risk" bucket and is now awaiting formal evaluation by the Pharmacy Compounding Advisory Committee (PCAC). Per FDA's announced schedule, GHK-Cu is slated for PCAC review in 2027 (a later date than several other peptides in the same April 2026 action, such as BPC-157 and TB-500, which are scheduled for the July 2026 PCAC meeting). Until PCAC review concludes and FDA makes a final determination, the substance's long-term standing on the 503A bulks list remains unresolved as of July 2026.
Providers should also note the separate movement on non-injectable GHK-Cu nominations on the 503A list; the status of specific dosage forms can differ, so confirming current standing with the compounding pharmacy for the exact form being ordered is prudent.
The bottom line for clinics
- GHK-Cu is not FDA-approved as a drug and is not equivalent to any approved product.
- Compounded GHK-Cu is prepared by a licensed pharmacy on a valid prescription within a prescriber-patient relationship — it is not an over-the-counter drug.
- The cosmetic-versus-drug classification of topical forms turns on claims; conservative, non-therapeutic marketing reduces regulatory exposure.
- The injectable form's Category 2 removal is a procedural step, not an approval, with PCAC review pending in 2027.
Clinics order compounded medications through platforms like ScriptLinkRx, which connect licensed practices with licensed 503A/503B compounding pharmacies; the platform does not change the underlying regulatory analysis, which remains the prescriber's and pharmacy's responsibility.
Sourcing and Quality: What to Ask a Compounding Pharmacy
Because GHK-Cu is not an approved drug product with a standardized reference, sourcing diligence matters — especially for injectable forms, where sterility is paramount. Providers should ask a prospective compounding pharmacy:
- API source and Certificate of Analysis (CoA) — where is the copper peptide API sourced, and can the pharmacy provide a CoA documenting identity and purity for each lot?
- USP compliance — does the pharmacy compound in accordance with USP General Chapters <795> (non-sterile) for topicals and <797> (sterile) for injectables, and <800> where applicable?
- Potency and sterility testing — for injectable preparations, what sterility, endotoxin, and potency testing is performed, and by whom? (Copper-containing sterile preparations warrant particular attention to endotoxin and contamination controls.)
- Beyond-use dating (BUD) — how is BUD assigned and substantiated for the specific formulation and packaging?
- State licensure and 503A/503B status — is the pharmacy properly licensed in the clinic's state, and is it operating as a 503A patient-specific compounder or a 503B outsourcing facility? This affects permissible practices and testing expectations.
- Formulation controls for combinations — for combination topicals, what stability and compatibility data support the specific mixture?
Frequently Asked Questions
Is GHK-Cu FDA-approved?
No. As of July 2026, GHK-Cu is not FDA-approved as a drug for any indication. Topical copper tripeptide-1 appears in cosmetics regulated as cosmetics (not pre-approved as drugs), and compounded GHK-Cu preparations are made by licensed pharmacies on valid prescriptions — neither of which constitutes FDA drug approval.
Does the April 2026 Category 2 removal mean injectable GHK-Cu is cleared for compounding?
No. Removal from FDA's Category 2 means the substance is no longer flagged as a significant safety risk in that interim list, but it is awaiting formal PCAC evaluation, expected in 2027. It is a procedural step, not an approval or a final compounding clearance.
What determines whether a topical GHK-Cu product is a cosmetic or a drug?
Largely the intended use, which FDA infers substantially from the claims made about the product. Appearance-focused claims generally align with cosmetic status, while claims to treat, cure, mitigate, or affect the structure or function of the body can move a product into drug territory. Marketing language is therefore a compliance decision, not just a copy decision.
What should clinics prioritize when sourcing injectable GHK-Cu?
Sterility and quality documentation: USP <797> compliance, sterility and endotoxin testing, potency verification, a lot-specific CoA, substantiated beyond-use dating, and confirmation of the pharmacy's licensure and 503A/503B status.
Related Reading
- See where GHK-Cu ranks among the most-prescribed compounded medications
- BPC-157 for providers: regulatory status and practice context
- Compounded glutathione: sterility and quality considerations
